Synaptogenix (NASDAQ:TAOX) Announces Quarterly Earnings Results

Synaptogenix (NASDAQ:TAOX – Get Free Report) posted its quarterly earnings results on Monday. The company reported $0.38 earnings per share (EPS) for the quarter, Zacks reports. Synaptogenix had a negative return on equity of 128.51% and a negative net margin of 2,153.97%.

Synaptogenix Stock Down 11.4%

NASDAQ TAOX traded down $0.24 on Monday, reaching $1.86. The company had a trading volume of 88,871 shares, compared to its average volume of 155,319. Synaptogenix has a 52 week low of $1.70 and a 52 week high of $7.85. The stock’s 50 day moving average is $3.60 and its 200-day moving average is $4.16. The stock has a market cap of $14.96 million, a price-to-earnings ratio of -0.48 and a beta of 1.81.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Wall Street Zen downgraded shares of Synaptogenix from a “hold” rating to a “sell” rating in a research note on Sunday, October 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Synaptogenix in a research note on Thursday, October 15th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company has a consensus rating of “Sell”.

View Our Latest Report on Synaptogenix

About Synaptogenix

(Get Free Report)

Synaptogenix was a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases and disorders involving impaired cognitive function. The company’s research centered on therapies intended to support synaptic function. Its lead investigational drug candidate was bryostatin-1, which it studied as a potential treatment for Alzheimer’s disease. The company also explored its approach in other conditions associated with cognitive impairment. Bryostatin-1 was investigational, not an approved medicine.

Read More

Earnings History for Synaptogenix (NASDAQ:TAOX)

Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.